Approach

Summary

Licensing status

Publication and contact information

Chemistry

Vascular catheters modified with polysulfobetaine to prevent thrombus formation and microbial attachment

Polysulfobetaine surface modification of vascular catheters could help prevent catheter-associated thrombosis and infection. Nonleaching polysulfobetaine was attached to the inner surface of commercially available, peripherally inserted central catheters. In a canine model of thrombosis, the polysulfobetaine-modified catheter showed a 99% decrease in thrombus formation compared with an unmodified catheter. The modified catheter also showed 97%-99.9% lower adhesion of 5 tested microbes and 97% less biofilm formation with Staphylococcus aureus than the unmodified catheter.
The Semprus BioSciences Corp. unit of Teleflex Inc. markets the polysulfobetaine-modified catheter in the EU, and the product is under FDA review.

SciBX 5(40); doi:10.1038/scibx.2012.1062
Published online Oct. 11, 2012

Covered by multiple issued and pending patents; licensing status undisclosed

Smith, R.S. et al. Sci. Transl. Med.; published online Sept. 26, 2012;
doi:10.1126/scitranslmed.3004120
Contact: Christopher Loose, Semprus BioSciences Corp., Cambridge, Mass.
e-mail:
chris.loose@semprusbio.com